Industry-Supported Labs Battle To Gain Respect

PALO ALTO, CALIF.—It wasn’t very good news for the public.., or for the electric power industry. Researchers had found that sulfur dioxide emissions from power plants could aggravate the condition of asthmatics. But the Electric Power Research Institute (EPRI), which financed the research, didn’t flinch. EPRI was created in 1972 to support research on subjects that are important to the electric utility industry. Its $379 million annual budget comes entirely from contribut

Written byRobert Buderi
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

PALO ALTO, CALIF.—It wasn’t very good news for the public.., or for the electric power industry. Researchers had found that sulfur dioxide emissions from power plants could aggravate the condition of asthmatics. But the Electric Power Research Institute (EPRI), which financed the research, didn’t flinch.

EPRI was created in 1972 to support research on subjects that are important to the electric utility industry. Its $379 million annual budget comes entirely from contributions by its 700 members. But that long list of subjects, which includes a search for more efficient fuels, a better understandmg of earthquakes, and an investigation into the health effects of power transmission lines, contains many issues that affect the public. And emissions from coal-burning plants is one of them.

That meant the findings—that asthmatics reported temporary bouts of coughing and wheezing induced by exercising near the power plants— belonged in the open literature. So EPRI had them ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies